交银国际每日晨报-20251021

Group 1: 康方生物 (Kangfang Biologics) - The report highlights that the PD-1 drug,依沃西, has shown significant improvement in progression-free survival (PFS) for first-line lung squamous cell carcinoma, with median PFS of 11.1 months compared to 6.9 months for the control group, achieving a hazard ratio of 0.60 and a p-value of <0.0001 [1] - The company has received acceptance for a new indication application from the CDE in July 2025, with peak sales expectations in mainland China projected at RMB 7.1 billion [1] - The report maintains a buy rating with a target price of HKD 183, indicating a potential upside of 49.3% from the closing price of HKD 122.60 [1][2] Group 2: 协鑫科技 (GCL-Poly Energy) - The report indicates that GCL-Poly has turned profitable in its photovoltaic materials segment, reporting a profit of RMB 960 million in Q3, largely driven by a significant increase in polysilicon prices since late July [3] - The company announced a plan to issue 4.74 billion shares at HKD 1.15 per share, raising approximately HKD 5.392 billion for capacity expansion and other purposes [3] - The new national standards for polysilicon energy consumption are expected to tighten significantly, which may benefit the elimination of outdated production capacity [3] Group 3: 互联网行业 (Internet Industry) - The report notes a steady growth in e-commerce, with adjusted online retail sales for physical goods increasing by 7.5% year-on-year in Q3 2025 [8] - Key players like Alibaba, JD, and Pinduoduo are expected to maintain robust growth, with Alibaba's GMV growth aligning with market trends and JD's retail growth remaining stable [8][9] - The report emphasizes the potential of instant retail as a growth driver, particularly with the extended promotional periods leading up to major sales events [8][9]